{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T01:20:36Z","timestamp":1780104036456,"version":"3.54.0"},"reference-count":27,"publisher":"e-Century Publishing Corporation","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Am J Transl Res"],"DOI":"10.62347\/llrm5612","type":"journal-article","created":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T08:57:12Z","timestamp":1761728232000},"page":"7868-7877","source":"Crossref","is-referenced-by-count":1,"title":["Efficacy and safety of ixazomib-lenalidomide-dexamethasone in relapsed\/refractory multiple myeloma patients"],"prefix":"10.62347","volume":"17","author":[{"given":"Xufei","family":"Huang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"48694","published-online":{"date-parts":[[2025]]},"reference":[{"key":"ref0","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1111\/ejh.14353","article-title":"Talquetamab in multiple myeloma: efficacy, safety, and future directions","volume":"114","author":"Labanca","year":"2025","unstructured":"Labanca C, Martino EA, Vigna E, Bruzzese A, Mendicino F, Lucia E, Olivito V, Puccio N, Neri A, Morabito F and Gentile M. Talquetamab in multiple myeloma: efficacy, safety, and future directions. Eur J Haematol 2025; 114: 386-399.","journal-title":"Eur J Haematol"},{"key":"ref1","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1080\/03007995.2025.2502125","article-title":"Epidemiology and approaches for management of relapsed and refractory multiple myeloma in gulf countries: a narrative review and insights from the Gulf multiple myeloma experts","volume":"41","author":"Alhuraiji","year":"2025","unstructured":"Alhuraiji A, Lal A, Al Mehairi A, Alam A, Mudawi D, Khan F, Al Nabhani I, El-Najjar I, Al-Farsi K, K Rana S, Wagdy T, Yassin MA, Rodriguez Otero P, Haddadin H and Aljabban A. Epidemiology and approaches for management of relapsed and refractory multiple myeloma in gulf countries: a narrative review and insights from the Gulf multiple myeloma experts. Curr Med Res Opin 2025; 41: 593-600.","journal-title":"Curr Med Res Opin"},{"key":"ref2","doi-asserted-by":"publisher","unstructured":"An G, Ge Z, Jing H, Liu J, Yang G, Feng R, Xu Z, Qi M, Wang J, Song J, Zhou W, Sun B, Zhu D, Chen X, Cui C and Qiu L. Subcutaneous daratumumab in Chinese patients with relapsed or refractory multiple myeloma: an open-label, multicenter, phase 1 study (MMY1010). Blood Sci 2024; 6: e00193.","DOI":"10.1097\/BS9.0000000000000193"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1007\/s12185-024-03800-5","article-title":"Isatuximab with pomalidomide-dexamethasone in relapsed\/refractory multiple myeloma: post-marketing surveillance in Japan","volume":"120","author":"Tagami","year":"2024","unstructured":"Tagami N, Uchiyama M, Suzuki K, Shirai H, Seto T, Nishina S and Iida S. Isatuximab with pomalidomide-dexamethasone in relapsed\/refractory multiple myeloma: post-marketing surveillance in Japan. Int J Hematol 2024; 120: 217-228.","journal-title":"Int J Hematol"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"2931","DOI":"10.3390\/cancers16172931","article-title":"Updates on therapeutic strategies in the treatment of relapsed\/refractory multiple myeloma","volume":"16","author":"Parekh","year":"2024","unstructured":"Parekh DS, Tiger YKR, Jamouss KT, Hassani J, Bou Zerdan M and Raza S. Updates on therapeutic strategies in the treatment of relapsed\/refractory multiple myeloma. Cancers (Basel) 2024; 16: 2931.","journal-title":"Cancers (Basel)"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1056\/NEJMoa2406536","article-title":"Talquetamab plus teclistamab in relapsed or refractory multiple myeloma","volume":"392","author":"YC","year":"2025","unstructured":"Cohen YC, Magen H, Gatt M, Sebag M, Kim K, Min CK, Ocio EM, Yoon SS, Chu MP, Rodriguez-Otero P, Avivi I, Quijano Carde NA, Kumar A, Krevvata M, Peterson MR, Di Scala L, Scott E, Hilder B, Vanak J, Banerjee A, Oriol A, Morillo D and Mateos MV; RedirecTT-1 Investigators and Study Group. Talquetamab plus teclistamab in relapsed or refractory multiple myeloma. N Engl J Med 2025; 392: 138-149.","journal-title":"N Engl J Med"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1111\/bjh.19570","article-title":"Twice-weekly induction with ixazomib-lenalidomide-dexamethasone (IRd) combination followed by extended IRd consolidation and lenalidomide maintenance in transplant-eligible patients with newly diagnosed multiple myeloma: results of the phase 2 study IFM2014-03","volume":"205","author":"Perrot","year":"2024","unstructured":"Perrot A, Roussel M, Lauwers-Cances V, Hulin C, Leleu X, Touzeau C, Facon T, Mariette C, Schiano JM, Gay J, Montes L, Ranta D, Huguet A, Wuilleme S, Dejoie T, Devlamynck L, Corre J, Avet-Loiseau H, Moreau P and Attal M. Twice-weekly induction with ixazomib-lenalidomide-dexamethasone (IRd) combination followed by extended IRd consolidation and lenalidomide maintenance in transplant-eligible patients with newly diagnosed multiple myeloma: results of the phase 2 study IFM2014-03. Br J Haematol 2024; 205: 891-899.","journal-title":"Br J Haematol"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1080\/17474086.2018.1518129","article-title":"Ixazomib: a novel drug for multiple myeloma","volume":"11","author":"Zanwar","year":"2018","unstructured":"Zanwar S, Abeykoon JP and Kapoor P. Ixazomib: a novel drug for multiple myeloma. Expert Rev Hematol 2018; 11: 761-771.","journal-title":"Expert Rev Hematol"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1080\/15384047.2018.1529095","article-title":"Ixazomib promotes CHOP-dependent DR5 induction and apoptosis in colorectal cancer cells","volume":"20","author":"Yue","year":"2019","unstructured":"Yue D and Sun X. Ixazomib promotes CHOP-dependent DR5 induction and apoptosis in colorectal cancer cells. Cancer Biol Ther 2019; 20: 284-294.","journal-title":"Cancer Biol Ther"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"1272528","DOI":"10.3389\/fonc.2023.1272528","article-title":"IMiD\/CELMoD-induced growth suppression of adult T-cell leukemia\/lymphoma cells via cereblon through downregulation of target proteins and their downstream effectors","volume":"13","author":"Wang","year":"2024","unstructured":"Wang Y, Shimosaki S, Ikebe E, Iha H, Yamamoto JI, Fife N, Ichikawa T, Hori M, Ogata M, Tsukamoto Y, Hijiya N, Moriyama M, Hagiwara S, Kusano S, Saito M, Ahmed K, Nishizono A, Handa H and Morishita K. IMiD\/CELMoD-induced growth suppression of adult T-cell leukemia\/lymphoma cells via cereblon through downregulation of target proteins and their downstream effectors. Front Oncol 2024; 13: 1272528.","journal-title":"Front Oncol"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/s41572-024-00529-7","article-title":"Multiple myeloma","volume":"10","author":"Malard","year":"2024","unstructured":"Malard F, Neri P, Bahlis NJ, Terpos E, Moukalled N, Hungria VTM, Manier S and Mohty M. Multiple myeloma. Nat Rev Dis Primers 2024; 10: 45.","journal-title":"Nat Rev Dis Primers"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1007\/s00277-013-1841-y","article-title":"“Real-world” data on the efficacy and safety of lenalidomide and dexamethasone in patients with relapsed\/refractory multiple myeloma who were treated according to the standard clinical practice: a study of the Greek Myeloma Study Group","volume":"93","author":"Katodritou","year":"2014","unstructured":"Katodritou E, Vadikolia C, Lalagianni C, Kotsopoulou M, Papageorgiou G, Kyrtsonis MC, Matsouka P, Giannakoulas N, Kyriakou D, Karras G, Anagnostopoulos N, Michali E, Briasoulis E, Hatzimichael E, Spanoudakis E, Zikos P, Tsakiridou A, Tsionos K, Anargyrou K, Symeonidis A, Maniatis A and Terpos E. “Real-world” data on the efficacy and safety of lenalidomide and dexamethasone in patients with relapsed\/refractory multiple myeloma who were treated according to the standard clinical practice: a study of the Greek Myeloma Study Group. Ann Hematol 2014; 93: 129-139.","journal-title":"Ann Hematol"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1007\/s00277-013-1893-z","article-title":"Lenalidomide with dexamethasone treatment for relapsed\/refractory myeloma patients in Korea-experience from 110 patients","volume":"93","author":"Kim","year":"2014","unstructured":"Kim K, Kim SJ, Voelter V, Suh C, Yoon SS, Lee JJ, Kwak JY, Ryoo HM, Kim YS, Moon JH, Park SK, Kim SH, Mun YC, Kim JS, Eom HS, Jo DY, Jun HJ, Kim KH, Lee JO, Lee JH and Min CK; Korean Multiple Myeloma Working Party (KMMWP). Lenalidomide with dexamethasone treatment for relapsed\/refractory myeloma patients in Korea-experience from 110 patients. Ann Hematol 2014; 93: 113-121.","journal-title":"Ann Hematol"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"1802","DOI":"10.1002\/ajh.27422","article-title":"Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management","volume":"99","author":"Rajkumar","year":"2024","unstructured":"Rajkumar SV. Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management. Am J Hematol 2024; 99: 1802-1824.","journal-title":"Am J Hematol"},{"key":"ref14","doi-asserted-by":"publisher","unstructured":"Zhou YL, Zhang JQ, Wang W, Bao L, Fang BJ, Gao D, Su LP, Chen WM and Yang GZ. Bortezomib, mitoxantrone hydrochloride liposome, and dexamethasone for relapsed\/refractory multiple myeloma: a multi-center, open-label phase I trial. Cancer Med 2025; 14: e70890.","DOI":"10.1002\/cam4.70890"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1097\/CM9.0000000000002108","article-title":"Cancer statistics in China and United States, 2022: profiles, trends, and determinants","volume":"135","author":"Xia","year":"2022","unstructured":"Xia C, Dong X, Li H, Cao M, Sun D, He S, Yang F, Yan X, Zhang S, Li N and Chen W. Cancer statistics in China and United States, 2022: profiles, trends, and determinants. Chin Med J (Engl) 2022; 135: 584-590.","journal-title":"Chin Med J (Engl)"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1038\/s41375-022-01531-2","article-title":"LocoMMotion: a prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed and\/or refractory multiple myeloma","volume":"36","author":"Mateos","year":"2022","unstructured":"Mateos MV, Weisel K, De Stefano V, Goldschmidt H, Delforge M, Mohty M, Cavo M, Vij R, Lindsey-Hill J, Dytfeld D, Angelucci E, Perrot A, Benjamin R, van de Donk NWCJ, Ocio EM, Scheid C, Gay F, Roeloffzen W, Rodriguez-Otero P, Broijl A, Potamianou A, Sakabedoyan C, Semerjian M, Keim S, Strulev V, Schecter JM, Vogel M, Wapenaar R, Nesheiwat T, San-Miguel J, Sonneveld P, Einsele H and Moreau P. LocoMMotion: a prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed and\/or refractory multiple myeloma. Leukemia 2022; 36: 1371-1376.","journal-title":"Leukemia"},{"key":"ref17","doi-asserted-by":"publisher","unstructured":"Cai Z, Xia Z, He AL, Dong YJ, Wang Y, Liao A, Song Y, Song Mm J, Uhlar C, Chastain K, Watkins L, Luo X, Huang L, Niu Z, Quijano Carde NA, Guo Y, Xu H, Verona RI, Zhou L, Li J, Fu W, Niu T and Du J. Efficacy, safety, and pharmacokinetics of teclistamab in Chinese patients with relapsed\/refractory multiple myeloma from the China cohort of MajesTEC-1. Cancer 2025; 131: e35665.","DOI":"10.1002\/cncr.35665"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"1905","DOI":"10.3390\/medicina60111905","article-title":"Outcomes of ixazomib treatment in relapsed and refractory multiple myeloma: insights from croatian cooperative group for hematologic diseases (KROHEM)","volume":"60","author":"Batinic","year":"2024","unstructured":"Batinic J, Dreta B, Rincic G, Mrdeza A, Jakobac KM, Kristo DR, Vujcic M, Pirsic M, Jonjic Z, Perisa V, Sincic Petricevic J, Coha B, Holik H, Valkovic T, Stanic M, Krecak I, Stojanovic A, Sajfert D and Basic-Kinda S. Outcomes of ixazomib treatment in relapsed and refractory multiple myeloma: insights from croatian cooperative group for hematologic diseases (KROHEM). Medicina (Kaunas) 2024; 60: 1905.","journal-title":"Medicina (Kaunas)"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1007\/s10637-021-01153-y","article-title":"A phase i study of ixazomib and erlotinib in patients with advanced solid tumors","volume":"40","author":"Kato","year":"2022","unstructured":"Kato S, Adashek JJ, Subbiah V, Fu S, Sun M, Nguyen L, Brown EJ, Yap TA, Karp DD, Piha-Paul SA and Hong DS. A phase i study of ixazomib and erlotinib in patients with advanced solid tumors. Invest New Drugs 2022; 40: 99-105.","journal-title":"Invest New Drugs"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1007\/s12012-023-09785-7","article-title":"Molecular cardiotoxic effects of proteasome inhibitors carfilzomib and ixazomib and their combination with dexamethasone involve mitochondrial dysregulation","volume":"23","author":"Jannuzzi","year":"2023","unstructured":"Jannuzzi AT, Korkmaz NS, Gunaydin Akyildiz A, Arslan Eseryel S, Karademir Yilmaz B and Alpertunga B. Molecular cardiotoxic effects of proteasome inhibitors carfilzomib and ixazomib and their combination with dexamethasone involve mitochondrial dysregulation. Cardiovasc Toxicol 2023; 23: 121-131.","journal-title":"Cardiovasc Toxicol"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"861709","DOI":"10.3389\/fonc.2022.861709","article-title":"Caspase-8: Friend or foe in bortezomib\/lenalidomide-based therapy for myeloma","volume":"12","author":"Zhou","year":"2022","unstructured":"Zhou L. Caspase-8: Friend or foe in bortezomib\/lenalidomide-based therapy for myeloma. Front Oncol 2022; 12: 861709.","journal-title":"Front Oncol"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1080\/14740338.2017.1344212","article-title":"Safety of ixazomib for the treatment of multiple myeloma","volume":"16","author":"Bonnet","year":"2017","unstructured":"Bonnet A and Moreau P. Safety of ixazomib for the treatment of multiple myeloma. Expert Opin Drug Saf 2017; 16: 973-980.","journal-title":"Expert Opin Drug Saf"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1007\/s12185-025-03927-z","article-title":"Real-world effectiveness of ixazomib, lenalidomide and dexamethasone in Asians with relapsed\/refractory multiple myeloma","volume":"121","author":"SC","year":"2025","unstructured":"Ng SC, Moon JH, Park SS, Koh Y, Lee JH, Eom HS, Shin HJ, Jung SH, Do YR, Wilfred G, Husin A, Kim HJ, Abdul Wahid S, Lee MW, Heo HW, Kim K and Chuncharunee S. Real-world effectiveness of ixazomib, lenalidomide and dexamethasone in Asians with relapsed\/refractory multiple myeloma. Int J Hematol 2025; 121: 670-683.","journal-title":"Int J Hematol"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"14930","DOI":"10.1096\/fj.202001340R","article-title":"Phosphorylation-dependent osterix degradation negatively regulates osteoblast differentiation","volume":"34","author":"Hoshikawa","year":"2020","unstructured":"Hoshikawa S, Shimizu K, Watahiki A, Chiba M, Saito K, Wei W, Fukumoto S and Inuzuka H. Phosphorylation-dependent osterix degradation negatively regulates osteoblast differentiation. FASEB J 2020; 34: 14930-14945.","journal-title":"FASEB J"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1111\/ejh.14292","article-title":"Efficacy of ixazomib, lenalidomide, dexamethasone regimen in daratumumab-exposed relapsed\/refractory multiple myeloma patients: a retrospective analysis","volume":"113","author":"Fric","year":"2024","unstructured":"Fric D, Stork M, Boichuk I, Sandecka V, Adam Z, Krejci M, Ondrouskova E, Fidrichova A, Radova L, Knechtova Z, Jarosova M and Pour L. Efficacy of ixazomib, lenalidomide, dexamethasone regimen in daratumumab-exposed relapsed\/refractory multiple myeloma patients: a retrospective analysis. Eur J Haematol 2024; 113: 810-816.","journal-title":"Eur J Haematol"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1007\/s11523-017-0524-3","article-title":"Dose and schedule selection of the oral proteasome inhibitor ixazomib in relapsed\/refractory multiple myeloma: clinical and model-based analyses","volume":"12","author":"Gupta","year":"2017","unstructured":"Gupta N, Yang H, Hanley MJ, Zhang S, Liu R, Kumar S, Richardson PG, Skacel T and Venkatakrishnan K. Dose and schedule selection of the oral proteasome inhibitor ixazomib in relapsed\/refractory multiple myeloma: clinical and model-based analyses. Target Oncol 2017; 12: 643-654.","journal-title":"Target Oncol"}],"container-title":["American Journal of Translational Research"],"original-title":[],"link":[{"URL":"https:\/\/e-century.us\/files\/ajtr\/17\/10\/ajtr0166573.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T01:49:37Z","timestamp":1769132977000},"score":1,"resource":{"primary":{"URL":"https:\/\/e-century.us\/files\/ajtr\/17\/10\/ajtr0166573.pdf"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"references-count":27,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.62347\/llrm5612","relation":{},"ISSN":["1943-8141"],"issn-type":[{"value":"1943-8141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025]]}}}